Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic can­cer drug suc­cess

CHICA­GO — With their lead drug — and AS­CO17 star — larotrec­tinib mak­ing the fi­nal run-up to a wide­ly ex­pect­ed ap­proval in No­vem­ber, Loxo On­col­o­gy $LOXO is back at the big can­cer con­fer­ence this year with its next drug in the pipeline. And LOXO-292 is blaz­ing a trail of pos­i­tive ear­ly-stage da­ta that may well fore­tell an­oth­er break­through for the biotech’s tis­sue-ag­nos­tic ap­proach to can­cer drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER